News & Updates
Showing Multidisciplinary articles
Showing
Ipilimumab plus nivolumab elicits response in mCRPC
Use of dual immune checkpoint inhibitors (ICIs), nivolumab and ipilimumab, exhibits responses in some molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC), including those with mismatch repair deficiency (dMMR), nonsynonymous tumour mutational burden ≥7.1 muts/Mb (hTMB), a BRCA2 mutation (BRCAm), or biallelic CDK12 inactivation (CDK12i).
Ipilimumab plus nivolumab elicits response in mCRPC
02 Jan 2025
Cuffless device may revolutionize hypertension management
A retrospective analysis shows that continual cuffless blood pressure (BP) monitoring may facilitate rapid and practical assessment of systolic BP (SBP) time-in-target range (TTR), an emerging metric of hypertension control.
Cuffless device may revolutionize hypertension management
02 Jan 2025
NT-proBNP predicts cardiorenal complications in Chinese patients with T2D
Elevated N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels independently predict cardiorenal complications in Chinese patients with type 2 diabetes (T2D) and can be utilized as a clinical prognostic biomarker for risk stratification to enable more intensive organ-protective treatment in those at risk, a study involving 1,993 patients enrolled in the Hong Kong Diabetes Biobank has shown.
